ArticleStem cells translational medicine2021
Ethical issues concerning a pay-to-participate stem cell study.
Article in Stem cells translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Why retracted articles can have an influential afterlife-and what to do about it.Stem cells translational medicine · 2026Article
- Ethical and Regulatory Considerations Related to Regenerative Medicine.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025Review
- Myths and Realities about the Private Sector Stem Cell Industry in Malaysia.Asian bioethics review · 2025Article
- Therapeutic potential of urine-derived stem cells in renal regeneration following acute kidney injury: A comparative analysis with mesenchymal stem cells.World journal of stem cells · 2024Article
- Ethical issues in direct-to-consumer healthcare: A scoping review.PLOS digital health · 2024Article
- Clinical use of autologous cell-based therapies in an evolving regulatory landscape: A survey of patient experiences and perceptions.F1000Research · 2023Article
- Retraction.Stem cells translational medicine · 2021Article
- Addressing concerns regarding associated costs, transparency, and integrity of research in recent stem cell trial.Stem cells translational medicine · 2021Article
- Ethical issues concerning a pay-to-participate stem cell study.Stem cells translational medicine · 2021Article
- Patients' Views on Paying to Participate in Clinical Trials.AJOB empirical bioethicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In our critique of a pay-to-participate study, we address how the failure to disclose study-related payments appears to have violated STEM CELLS Translational Medicine's editorial policies concerning conflict-of-interest and financial disclosure. Our analysis also identifies broader ethical issues and scientific concerns related to pay-to-participate studies conducted by businesses with a record of selling purported stem cell treatments before determining whether the products they sell are safe and efficacious. Authors of peer-reviewed articles have a responsibility to comply with journal policies and disclose financial conflicts of interest to editors, reviewers, and readers. Authors should also disclose when stem cell interventions being tested in clinical trials have already been sold on a direct-to-consumer basis as "stem cell treatments" by authors' affiliate institutions. Financial conflicts of interest and other forms of possible bias must be disclosed to put clinical studies in context and facilitate the critical assessment of research methods, findings, and conclusions. The apparent failure to comply with journal editorial policies and disclose such financial conflicts warrants careful investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.